• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Stone formation by Ureaplasma urealyticum in human urine and its prevention by urease inhibitors.

作者信息

Takebe S, Numata A, Kobashi K

出版信息

J Clin Microbiol. 1984 Nov;20(5):869-73. doi: 10.1128/jcm.20.5.869-873.1984.

DOI:10.1128/jcm.20.5.869-873.1984
PMID:6549013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC271462/
Abstract

When Ureaplasma urealyticum T-960 was inoculated into normal human urine (10(8) viable cells per ml of urine), a white precipitate formed, with an increase in pH of the infected urine. This precipitate was identified as a mixture of struvite and whitelockite by analysis of the infrared spectrum. Its formation was completely prevented by the addition of 10 microM N-benzoylphosphotriamide, 20 microM N-isopentenoylphosphotriamide, or 0.5 mM caprylohydroxamic acid without the alkalinization of the urine, and the Ureaplasma color change units were also decreased markedly by these compounds. The apparent concentrations for 50% inhibition by N-benzoylphosphotriamide,N-isopentenolyphosphotriamide, and caprylohydroxamic acid against Ureaplasma urease were 7 nM, 2 nM, and 2.2 microM, respectively. From these results, it seems that stone formation by U. urealyticum is prevented with these compounds, that prevention being directly attributable to the inhibition of urease activity, which causes the death of the cells.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d0/271462/58fb4d79866a/jcm00124-0073-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d0/271462/58fb4d79866a/jcm00124-0073-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d0/271462/58fb4d79866a/jcm00124-0073-a.jpg

相似文献

1
Stone formation by Ureaplasma urealyticum in human urine and its prevention by urease inhibitors.
J Clin Microbiol. 1984 Nov;20(5):869-73. doi: 10.1128/jcm.20.5.869-873.1984.
2
Ureaplasma urealyticum-induced crystallization of magnesium ammonium phosphate and calcium phosphates in synthetic urine.解脲脲原体诱导合成尿液中磷酸镁铵和磷酸钙结晶
J Urol. 1984 Oct;132(4):795-9. doi: 10.1016/s0022-5347(17)49876-4.
3
[Urinary calculi and infection].[尿路结石与感染]
Urologia. 2014 Apr-Jun;81(2):93-8. doi: 10.5301/uro.5000073. Epub 2014 May 27.
4
Therapy for urolithiasis with hydroxamic acids. IV. Prevention of infected urinary stone formation with N-(pivaloyl)glycinohydroxamic acid.
J Pharmacobiodyn. 1981 Jul;4(7):469-74. doi: 10.1248/bpb1978.4.469.
5
Urinary infection stones caused by Ureaplasma urealyticum: a review.解脲脲原体引起的泌尿感染结石:综述
Scand J Infect Dis Suppl. 1988;53:46-9.
6
Ureaplasma urealyticum as a causative organism of urinary tract infection stones.解脲脲原体作为尿路感染结石的致病微生物。
J Egypt Public Health Assoc. 1996;71(3-4):309-19.
7
Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticum.质子泵抑制剂兰索拉唑对解脲脲原体的生长抑制作用:直接归因于兰索拉唑对解脲脲原体脲酶活性及尿素诱导的ATP合成的抑制。
Antimicrob Agents Chemother. 1995 Oct;39(10):2187-92. doi: 10.1128/AAC.39.10.2187.
8
Ureaplasma-urealyticum-induced bladder stones in rats and their prevention by flurofamide and doxycycline.解脲脲原体诱导大鼠膀胱结石及其通过氟洛酰胺和强力霉素进行预防
Isr J Med Sci. 1987 Jun;23(6):565-7.
9
Inhibition of the growth of Ureaplasma urealyticum by a new urease inhibitor, flurofamide.新型脲酶抑制剂氟罗酰胺对解脲脲原体生长的抑制作用
Yale J Biol Med. 1983 Sep-Dec;56(5-6):717-22.
10
Purification and characterization of urease from Ureaplasma urealyticum.解脲脲原体脲酶的纯化与特性分析
Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Aug;269(2):160-7. doi: 10.1016/s0176-6724(88)80092-0.

引用本文的文献

1
Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust.结痂性尿道病:全面概述——深入探究痂皮之下
Front Med (Lausanne). 2021 Jan 21;7:609024. doi: 10.3389/fmed.2020.609024. eCollection 2020.
2
The Human Ureaplasma Species as Causative Agents of Chorioamnionitis.人脲原体作为绒毛膜羊膜炎的病原体
Clin Microbiol Rev. 2016 Dec 14;30(1):349-379. doi: 10.1128/CMR.00091-16. Print 2017 Jan.
3
Urease from a potentially pathogenic coccoid isolate: purification, characterization, and comparison to other microbial ureases.

本文引用的文献

1
Specific inhibition of urease by hydroxamic acids.异羟肟酸对脲酶的特异性抑制作用。
Biochim Biophys Acta. 1962 Dec 4;65:380-3. doi: 10.1016/0006-3002(62)91067-3.
2
Adenosine 5'-triphosphate synthesis induced by urea hydrolysis in Ureaplasma urealyticum.解脲脲原体中尿素水解诱导的腺苷5'-三磷酸合成
J Bacteriol. 1980 Nov;144(2):830-2. doi: 10.1128/jb.144.2.830-832.1980.
3
Flurofamide: a potent inhibitor of bacterial urease with potential clinical utility in the treatment of infection induced urinary stones.氟乙酰胺:一种强效的细菌脲酶抑制剂,在治疗感染性尿路结石方面具有潜在的临床应用价值。
来自潜在致病性球状分离株的脲酶:纯化、表征及与其他微生物脲酶的比较
Infect Immun. 1997 Oct;65(10):3991-6. doi: 10.1128/iai.65.10.3991-3996.1997.
4
Ureaplasma urealyticum-induced urinary tract stones in rats.解脲脲原体诱导的大鼠尿路结石
Urol Res. 1996;24(6):345-8. doi: 10.1007/BF00389791.
5
Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticum.质子泵抑制剂兰索拉唑对解脲脲原体的生长抑制作用:直接归因于兰索拉唑对解脲脲原体脲酶活性及尿素诱导的ATP合成的抑制。
Antimicrob Agents Chemother. 1995 Oct;39(10):2187-92. doi: 10.1128/AAC.39.10.2187.
6
Organization of Ureaplasma urealyticum urease gene cluster and expression in a suppressor strain of Escherichia coli.解脲脲原体脲酶基因簇的组织及其在大肠杆菌抑制菌株中的表达。
J Bacteriol. 1996 Feb;178(3):647-55. doi: 10.1128/jb.178.3.647-655.1996.
7
In vitro and in vivo study of stone formation by Corynebacterium group D2 (Corynebacterium urealyticum).
J Clin Microbiol. 1986 Apr;23(4):691-4. doi: 10.1128/jcm.23.4.691-694.1986.
8
Genetic analysis of an Escherichia coli urease locus: evidence of DNA rearrangement.大肠杆菌脲酶基因座的遗传分析:DNA重排的证据
J Bacteriol. 1988 Mar;170(3):1041-5. doi: 10.1128/jb.170.3.1041-1045.1988.
9
Alternative therapy for genital mycoplasma infections.
Eur J Clin Microbiol Infect Dis. 1988 Oct;7(5):603-5. doi: 10.1007/BF01964235.
10
Infections caused by antibiotic-resistant Corynebacterium group D2.由耐抗生素的D2群棒状杆菌引起的感染。
Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):337-41. doi: 10.1007/BF01962333.
J Urol. 1982 Feb;127(2):346-50. doi: 10.1016/s0022-5347(17)53779-9.
4
Therapy for urolithiasis by hydroxamic acids. III. Urease inhibitory potency and urinary excretion rate of N-acylglycinohydroxamic acids.
J Pharmacobiodyn. 1980 Sep;3(9):451-6. doi: 10.1248/bpb1978.3.451.
5
Prevention of infected urinary stones in rats by urease inhibitor: a new hydroxamic acid derivative.脲酶抑制剂对大鼠感染性尿路结石的预防作用:一种新型异羟肟酸衍生物
Invest Urol. 1980 Sep;18(2):102-5.
6
Mutagenicity of N-acylglycinohydroxamic acids and related compounds.
J Pharmacobiodyn. 1980 Nov;3(11):557-61. doi: 10.1248/bpb1978.3.557.
7
Treatment of infected urinary stones in rats by a new hydroxamic acid, "N-(pivaloyl)glycinohydroxamic acid.
Urol Res. 1982;10(4):217-9. doi: 10.1007/BF00255948.
8
Adherence of mycoplasmas to glass and plastic.支原体对玻璃和塑料的黏附性。
J Bacteriol. 1967 Nov;94(5):1781-2. doi: 10.1128/jb.94.5.1781-1782.1967.
9
Occurrence of urease in T strains of Mycoplasma.脲酶在支原体T株中的存在情况。
J Bacteriol. 1967 May;93(5):1513-20. doi: 10.1128/jb.93.5.1513-1520.1967.
10
[Direct colorimetry of ammonia in the blood].
Saishin Igaku. 1966 Mar;21(3):622-7.